GlassScriptPhysician profile
Amanda Chagolla
NPI 1184237885
$7,726.88
in general payments reported to CMS, 2019-2025
23 companies · $1,318 in 2025
The $1,318 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $861 · 2023: $1,769 · 2024: $3,302 · 2025: $1,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,372 · Education: $17.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,371.94 |
| Education | $17.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,969.83 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $1,224.60 | 2023-2025 | |
| Axsome Therapeutics, INC. | $936.51 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $505.81 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $473.49 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Ironshore Pharmaceuticals INC. | $473.38 | 2023-2024 | Jornay Pm |
| Corium, LLC | $419.55 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $264.01 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Tris Pharma INC | $222.16 | 2023-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $219.19 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $169.89 | 2024-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $159.07 | 2021-2022 | |
| Lundbeck LLC | $152.79 | 2023-2025 | Rexulti |
| Alkermes, INC. | $138.32 | 2023-2025 | Aristada, Lybalvi |
| Noven Therapeutics, LLC | $85.92 | 2023-2024 | Xelstrym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $81.49 | 2023 | Xelstrym |
| Vertical Pharmaceuticals, LLC | $61.06 | 2024 | Relexxii, Methylphenidate Hydrochloride |
| Takeda Pharmaceuticals U.S.A., INC. | $48.59 | 2021-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $32.63 | 2024-2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $32.30 | 2023 | Daybue |
| Almatica Pharma LLC | $22.11 | 2023 | Loreev Xr |
| Sage Therapeutics, LLC | $19.88 | 2025 | Zurzuvae |
| Neos Therapeutics, LP | $14.30 | 2023 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Chagolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.